Consolidation of Sub-National Commissioning in the UK

Published on January 19, 2023

UK healthcare is transitioning from Clinical Commissioning Groups to the Integrated Care System. This change will have a significant ripple effect on a sub-national level. Industry experts Sara Jacobs, Graham Tatham and Rachel Rowbottom explain how this will affect manufacturers and what steps they need to take for continued growth.

Special thanks to Sam Calderwood for contributing to this article.

Alongside national level reforms, important changes are occurring to the sub-national landscape which will directly impact the commercialization of medicines in the UK. Evolving stakeholder roles, transition of budget holder responsibility, and other funding reforms will require manufacturers to adapt their strategy in order to optimize access and ensure successful uptake, especially in competitive indications.

Transition to the Integrated Care System (ICS)

There are multiple influencing factors increasing the relevance…

Continue reading on website
Other news

Shifts in Provider Reimbursement and How Manufacturers Should Respond

January 19, 2023
*//*-->*//*-->*//*-->*//*-->*//*-->*/Value-based payments for providers are gaining momentum in the United States. Pharma and Biotech manufacturers, as well as other players in the ecosystem, must recognize how this changes provider incentives and behavior, and adjust accordingly.The US healthcare system has long struggled with significant costs without a corresponding improvement in public health

Cell & Gene Therapy: Curing the 'Incurable'

January 19, 2023
Until recently, there had been multiple breakthrough therapies for rare diseases but few cures. Now, advancements in CGT (cell and gene therapies) create possibilities to cure the “incurable”. Yet behind the scenes, each wave of innovation poses challenges for manufacturers, healthcare systems, and payers. We interviewed pharmaceutical Pricing & Market Access experts, Dirk Kars and Christian Schul